Hepatocellular carcinoma: clinical frontiers and perspectives

By Jordi Bruix1 , 2, G. Gores, V. Mazzaferro. Gut, 2014

1,329 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/9ce6b5b9b6cf934a4ae3770e085d40888465aad0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. J. Llovet
2. Jordi Bruix1 , 2
3. V. Mazzaferro
4. Peter R. Galle
5. Alejandro Forner1 , 2
6. M. Kudo
7. María E. Reig1 , 2
8. X. Forns

In Hepatology

1. J. Llovet
2. Jordi Bruix1 , 2
3. V. Mazzaferro
4. Alejandro Forner1 , 2
5. María E. Reig1 , 2
6. Peter R. Galle
7. J. Raoul
8. F. Piscaglia

Citations in the corpus

• EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. (2018, background): “considered at the time of LT listing for HCC, as competitive non-transplant options exist for the large majority of patients with well-preserved liver function.(437,438) Particularly, transplant benefit (TB) considerations should be added to the conventional principles of urgency and utility when de”
• Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update (2017, background): “It is now a matter of debate how best to select those to be offered LR or LT among HCC patients [408].”
• Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. (2016, background): “As known, recurrence after initial complete response may be due to dissemination of cells prior to treatment and to the emergence of new oncogenic clones within the underlying cirrhotic liver that has already received the genetic damage [15].”